Skip to main content

Valeo Pharmainc(VPH-T)
TSX

Today's Change
Real-Time Last Update

VALEO PHARMA AMENDS AGREEMENT WITH NOVARTIS PHARMACEUTICALS CANADA FOR (Pr)XIIDRA® IN CANADA AND CREDIT FACILITY WITH SAGARD HEALTHCARE ROYALTY PARTNERS, LP

Newswire.ca - Fri Feb 2, 4:03PM CST

/NOT FOR DISTRIBUTION TO U.S. NEWS WIRE SERVICES OR DISSEMINATION IN THE UNITED STATES/

MONTREAL, Feb. 2, 2024 /CNW/ - Valeo Pharma Inc. (TSX: VPH) (OTCQB: VPHIF) (FSE: VP2) ("Valeo"), a Canadian pharmaceutical company, announced today that it has entered into an amendment (the "Amendment") of its 7-year Commercialization and Supply Agreement (the "Commercialization and Supply Agreement") of XIIDRA® and SIMBRINZA® originally entered into with Novartis Pharmaceuticals Canada Inc. ("Novartis") in July 2022. For sake of clarity SIMBRINZA® is a registered trademark of Novartis AG while XIIDRA® is a registered trademark of Bausch and Lomb. The use of both trademarks has been authorized only in the context of this press release.

Read more at newswire.ca

Provided Content: Content provided by Newswire.ca. The Globe and Mail was not involved, and material was not reviewed prior to publication.

More from The Globe